Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$86.72 USD
-0.64 (-0.73%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$86.72 USD
-0.64 (-0.73%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Zacks News
Mallinckrodt (MNK) Looks Strong on Acthar, Generics Weak
by Zacks Equity Research
Mallinckrodt undertaking strategic acquisitions and divestitures to evolve as a high-performing specialty pharmaceutical company.
Zacks.com featured highlights: Broadcom Limited, CBRE Group, Sandvik AB, Applied Materials and Gilead Sciences
by Zacks Equity Research
Zacks.com featured highlights: Broadcom Limited, CBRE Group, Sandvik AB, Applied Materials and Gilead Sciences
Gilead (GILD) NDA for HIV Combo Regimen Gets Priority Review
by Zacks Equity Research
Gilead Sciences, Inc.'s(GILD) NDA for an investigational, fixed-dose combination of bictegravir for the treatment of HIV-1 infection obtained priority review.
5 Discounted PEG Stocks for GARP Investors
by Zacks Equity Research
PEG ratio is categorized under value investing and follows the principles of both growth and value investing.
Forget Teva (TEVA), Buy These 4 Drug Stocks Instead
by Arpita Dutt
With generic drugmakers like Teva (TEVA) under pressure, here is a look at four drug stocks that look well-positioned.
Markets Remain Choppy on Continuing Conflicts: 5 Top Picks
by Supriyo Bose
ROE helps investors distinguish between profit-generating companies from profit burners and is useful for determining the financial health of a company.
Alnylam (ALNY) Q2 Loss Narrower than Expected, Sales Miss
by Zacks Equity Research
Alnylam's (ALNY) second-quarter results were mixed with the company reporting a narrower-than-expected loss but sales missed estimates.
Top Ranked Income Stocks to Buy for August 10th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, August 10th:
Valeant (VRX) Beats Q2 Earnings, Sales in Line, Trims View
by Zacks Equity Research
Valeant's (VRX) second-quarter results were encouraging but the company trimmed its guidance due to recent divestitures.
Mylan (MYL) Misses on Q2 Earnings & Sales, Lowers View
by Zacks Equity Research
Mylan N.V. (MYL) reported disappointing second-quarter 2017 results wherein both earnings and sales missed estimates. The company also lowered its guidance.
Prothena (PRTA) Q2 Loss Narrows as Roche Makes $30M Payment
by Zacks Equity Research
Prothena Corporation plc (PRTA) reported a narrower-than-expected loss in the second quarter as the company received a milestone payment from Roche.
Mallinckrodt (MNK) Tops Q2 Earnings, Generics Segment Weak
by Zacks Equity Research
Mallinckrodt Public Limited Company (MNK) reported second-quarter 2017 results wherein earnings beat expectations but sales missed the same.
Forget Bayer, Buy These 3 Drug Stocks Instead
by Arpita Dutt
With Bayer (BAYRY) reporting mixed results in the second quarter and lowering its outlook, here is a look at 3 drug stocks which look well positioned.
Drug Stocks Q2 Earnings Roster for Aug 8: ACAD, JAZZ & More
by Zacks Equity Research
A look at the pharma/biotech companies that are set to report second-quarter results on Aug 8.
Top Ranked Momentum Stocks to Buy for August 7th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 7th:
Infinity (INFI) Q2 Loss Wider than Expected, View Intact
by Zacks Equity Research
Infinity Pharmaceuticals, Inc. (INFI) reported a wider-than-expected loss in second-quarter 2017 due to the termination of an agreement with AbbVie.
Radius (RDUS) Q2 Loss Wider than Expected on Higher Expenses
by Zacks Equity Research
Radius Health, Inc. (RDUS) posted a wider-than-expected loss in the second quarter due to an increase in general and administrative expenses.
Regeneron (REGN) Beats on Q2 Earnings & Sales, Raises View
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) reported strong second-quarter results wherein both earnings and sales beat expectations on the back of Eylea sales.
Aerie (AERI) Reports Narrower-Than-Expected Loss in Q2
by Zacks Equity Research
Aerie Pharmaceuticals, Inc.'s (AERI) narrower-than-expected loss in the second quarter was encouraging.
Top Ranked Income Stocks to Buy for August 2nd
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, August 2nd:
Intercept (ICPT) Posts Narrower-than-Expected Loss in Q2
by Zacks Equity Research
Intercept Pharmaceuticals (ICPT) reported a narrower-than-expected loss in Q2 on the back of higher Ocaliva sales.
United Therapeutics (UTHR) Incurs Loss in Q2, Sales Top
by Zacks Equity Research
United Therapeutics Corporation (UTHR) incurred a loss in Q2. However, stronger sales across the PAH franchise pulled up the top line in the quarter.
4 Drug Stocks in Focus this World Hepatitis Day
by Arpita Dutt
Does the hepatitis C virus (HCV) market still hold potential for companies like Gilead (GILD)?
Gilead (GILD) Tops Q2 Earnings& Revenue Estimates, Stock Up
by Zacks Equity Research
Gilead Sciences' (GILD) better-than-expected second-quarter results boosted investors sentiments.
Gilead (GILD) Shares Pop on Q2 Earnings and Revenue Beats
by Ryan McQueeney
Gilead Sciences (GILD) just released its second-quarter financial results, posting non-GAAP diluted earnings of $2.56 and revenues of $7.14 billion.